Anika Q2 2022 Earnings Report
Key Takeaways
Anika Therapeutics reported solid second quarter results, with continued momentum in their regenerative solutions portfolio. The company received FDA 510(k) clearance for their X-Twist Fixation System and is on track for a limited market release in the second half of the year.
Second quarter revenue growth was up 4%.
X-Twist 510(k) clearance was received.
Limited market release of X-Twist is on schedule for the second half of 2022.
The company is on track for achieving its stated full year guidance.
Anika
Anika
Forward Guidance
The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021. There remains volatility and uncertainty in the global macroeconomic environment and the Company’s outlook for fiscal 2022 is subject to the changing dynamics associated with staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the COVID pandemic.
Challenges Ahead
- Staffing shortages
- Supply chain disruption
- Inflation
- Direct and indirect impacts of the COVID pandemic
- Volatility and uncertainty in the global macroeconomic environment